Um tipo agressivo de câncer, chamado mesotelioma, que se forma na membrana que reveste o abdômen e os órgãos internos (o peritônio). As pessoas geralmente sentem dor na barriga e acúmulo de líquido nessa região (conhecido como barriga d'água).
Introdução
O que você precisa saber de cara
Um tipo agressivo de câncer, chamado mesotelioma, que se forma na membrana que reveste o abdômen e os órgãos internos (o peritônio). As pessoas geralmente sentem dor na barriga e acúmulo de líquido nessa região (conhecido como barriga d'água).
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 5 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 10 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Mesotelioma peritoneal maligno
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
12 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
50 ensaios clínicos encontrados, 18 ativos.
Publicações mais relevantes
Pretreatment volume-based 18F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients.
This study was conducted to examine relationships of pretreatment volume-based quantitative 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters with overall survival (OS) in malignant peritoneal mesothelioma (MPeM) patients. Data for 71 patients with FDG-avid MPeM who underwent pretreatment 18F-FDG PET/CT were retrospectively reviewed. The highest maximum standardized uptake value (SUVmax), metabolic tumor volume (WB MTV), and total lesion glycolysis (WB TLG) were calculated, including primary tumors and metastatic lesions. Relationships of clinicopathological factors (histological subtype, primary peritoneal disease form, abdominal nodal metastasis, extra-abdominal metastasis, treatment regimen), as well as volume-based quantitative PET/CT parameters with OS were evaluated using a Cox proportional hazards model and log-rank test. Enrolled patients underwent follow-up for a mean period of 27.6 months (range 2.1-161.2 months, median 18.9 months), during which 49 (69.0%) died. Receiver operating characteristic curve analysis and log-rank testing indicated that those with high SUVmax (≥ 6.9), WB MTV (≥ 60), or WB TLG (≥ 230) had a significantly lower OS rate than patients with a low rate (< 6.9, < 60, < 230; p = 0.0002, p < 0.0001, p < 0.0001, respectively). Univariate analysis of all patients indicated an association of diffuse peritoneal disease form (p = 0.022), high level SUVmax (p = 0.0002), WB MTV (p < 0.0001), or WB TLG (p < 0.0001) level, extra-abdominal metastasis (p = 0.079) and treatment regimen (p = 0.058) with significantly shorter OS. Additionally, multivariate analysis results confirmed high WB MTV as an independent negative predictor (hazard ratio 2.51, 95% confidence interval 0.72-13.45; p = 0.039). These findings indicate that pretreatment volume-based quantitative 18F-FDG PET/CT parameters, especially whole-body MTV, may be useful as surrogate markers for MPeM prognosis.
Genomic sequencing of multicystic mesothelioma finds cohesin complex mutations associated with disease recurrence in patients referred for cytoreductive surgery and HIPEC.
Multicystic mesothelioma (MCM) is a rare disease and there is debate about it's neoplastic nature with a spectrum of disease behaviour and little known about the genomic profile. In contrast, the genomic profile of malignant peritoneal mesothelioma (MPeM) is characterised. We characterized 24 MCM and 18 MPeM cases across a panel of cancer related regions and expanded to whole-exome sequencing for 11 MCMs. Validation by amplicon sequencing and functional assessment by molecular dynamic simulation were carried out. Kaplan-Meier analysis was carried out to assess recurrence-free survival. Few mutations were identified in MCMs across the panel. Exome sequencing revealed 28 genes mutated in >1 MCM case. We saw significant overrepresentation of mutations in the cohesin complex in SMC3, SMC1A, and STAG3. Multiple mutations in SMC3 at codon p.E1144 indicated a mutational hotspot. Molecular dynamics simulations showed mutation at this site impacts the protein function. Amplicon sequencing confirmed hotspot mutations in further MCMs. We observed a significant association (p = 0.0302) of mutation in SMC3 or SMC1A with disease recurrence. We see recurrent somatic mutations in MCMs particularly at a novel mutational hotspot in SMC3, consistent with a neoplastic process. Mutations in cohesin complex genes are associated with disease recurrence.
Ten-year of French multicentric experience in the management of peritoneal mesothelioma with 924 patients.
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare disease for which only selected patients are eligible for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of our study was to evaluate oncologic outcomes of different treatments patterns of DMPM at national level. All patients treated for DMPM between 2012 and 2021 in France were extracted through a national administrative database. Perioperative outcomes were analyzed into 3 groups: upfront-resectable, borderline-resectable (B-R) and inoperable patients. Survival outcomes were performed by Kaplan-Meier method. A multivariate logistic model was used to identify factors affecting survival. Of 924 patients, 270, 117 and 537 were identified as upfront-resectable, B-R and inoperable patients. The median age was 53 years with a mean Elixhauser comorbidity index of 3.2. Patients treated with CRS-HIPEC were younger with less comorbidities and had more exploratory laparoscopy compared to inoperable patients (p < 0.001). Majority of surgical patients were mostly treated in expert centers (97.7%). 90-day postoperative mortality (POM) was 2.1%. Major morbidity (MM) occurred in 50.9% with a failure-to-rescue (FTR) rate of 4.1%. Upfront-resectable patients had significantly better 5-year survival compared to B-R and inoperable patients (84.6% vs 55% vs 12.9%, p < 0.0001). After multivariate analysis, male gender (p < 0.0001), age (p = 0.005), B-R group (p < 0.0001), MM (p = 0.003) and adjuvant chemotherapy (p = 0.01) were independently associated with decrease 5-year survival. CRS and HIPEC is a safe procedure with a low 90-day POM and FTR. Patients should be address to expert centers to evaluate patients that could benefit from curative strategy.
Novel EWSR1::TEAD3 Fusion in an Adolescent With a Highly Aggressive Peritoneal Mesothelioma.
Malignant peritoneal mesothelioma (MPM) is an exceptionally rare entity in children and adolescents, exhibiting distinct clinicopathological features compared to its adult counterpart. Unlike adult cases, it typically occurs without a history of asbestos exposure or BAP1 inactivation. Although several driver gene fusions have been documented, the primary oncogenic triggers and molecular pathways involved remain largely undefined. Herein, we present an 18-year-old male who presented with ascites and abdominal distension. Computed tomography imaging revealed diffuse thickening of the peritoneum, including the omentum and mesentery. Histopathological examination showed a neoplasm composed of a mixture of atypical epithelioid and spindled cells infiltrating the adipose tissue. Immunohistochemically, the tumor cells were positive for cytokeratin, calretinin, CK5/6, and D2-40, and negative for CK20, MOC-31, and Ber-EP4, supporting the diagnosis of a biphasic mesothelioma. Molecular genetic studies identified a novel EWSR1::TEAD3 gene fusion. This is the first reported case of a peritoneal mesothelioma harboring this fusion.
Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study.
To investigate the efficacy and safety of pemetrexed/platinum-based chemotherapy combined with or without bevacizumab after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of patients with malignant peritoneal mesothelioma (MPM). A retrospective non-randomized study was performed on 205 MPM patients treated with CRS+HIPEC at our institution. A total of 97 eligible patients were analyzed: 58 patients who received postoperative chemotherapy combined with bevacizumab (C&B) and 39 patients who received chemotherapy alone (C) were divided into a study group and a control group, respectively. The patients were also divided into the bevacizumab-exposed subgroup and the bevacizumab-unexposed subgroup based on whether they had a history of bevacizumab infusion. Clinicopathological data and follow-up information were statistically analyzed. Independent prognostic factors were identified via survival analysis, and the safety of combination therapy was assessed via adverse event analysis. As of the follow-up cutoff date of July 1, 2025, in both the subgroups with and without a history of bevacizumab infusion, there was no statistically significant difference between the control and study groups in baseline pathological characteristic parameters (p > 0.05). Survival analysis revealed that in the subgroup of patients with a history of bevacizumab infusion, the difference in median overall survival (mOS) between the control and study groups was statistically significant (31.9 months vs. NR; p = 0.031), and the difference in median disease-free survival (mDFS) between the control and study groups was statistically significant (12.5 months vs. NR; p = 0.001); in the subgroup of patients without a history of bevacizumab infusion, the difference in mOS between the control and study groups was also statistically significant (20.5 months vs. NR; p = 0.001), and the difference in mDFS between the control and study groups was statistically significant (13.2 vs. 36.2 months; p = 0.001). The Cox regression model found that postoperative C&B was an independent prognostic factor (p = 0.009, HR = 0.081, 95% CI: 0.012-0.526) in the subgroup with a history of bevacizumab infusion, and the Ki-67 index (p = 0.043, HR = 2.563, 95% CI: 1.029-6.386) and postoperative C&B were independent prognostic factors (p = 0.01, HR = 0.086, 95% CI: 0.032-0.232) in the subgroup with no bevacizumab treatment history. A total of 101 cases of grade 1~2 adverse events in the study group were revealed via adverse event analysis, with common events including nausea/vomiting, fatigue, leukopenia/neutropenia, thrombocytopenia, anemia, abnormal liver function, hypertension, and proteinuria. There were four cases with grade 3 adverse events, mainly leukopenia/neutropenia, hypertension, and proteinuria. In the control group, there were 84 cases of grade 1~2 adverse events, and three cases of grade 3 adverse events were observed. Our exploratory findings suggest that bevacizumab combined with pemetrexed/platinum-based chemotherapy may be a therapeutic option for MPM patients after CRS+HIPEC; however, a prospective, randomized controlled clinical study is needed to validate our findings.
Publicações recentes
Pretreatment volume-based (18)F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients.
Genomic sequencing of multicystic mesothelioma finds cohesin complex mutations associated with disease recurrence in patients referred for cytoreductive surgery and HIPEC.
Ten-year of French multicentric experience in the management of peritoneal mesothelioma with 924 patients.
Novel EWSR1::TEAD3 Fusion in an Adolescent With a Highly Aggressive Peritoneal Mesothelioma.
Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study.
📚 EuropePMC617 artigos no totalmostrando 197
Pretreatment volume-based 18F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients.
Japanese journal of radiologyGenomic sequencing of multicystic mesothelioma finds cohesin complex mutations associated with disease recurrence in patients referred for cytoreductive surgery and HIPEC.
British journal of cancerTen-year of French multicentric experience in the management of peritoneal mesothelioma with 924 patients.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyNovel EWSR1::TEAD3 Fusion in an Adolescent With a Highly Aggressive Peritoneal Mesothelioma.
Genes, chromosomes & cancerAnalysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study.
Frontiers in oncologyNeoadjuvant Pressurized Intraperitoneal Aerosol Chemotherapy for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma: A Report of 2 Cases.
The American journal of case reportsPeritoneal mesothelioma as an incidental finding during inguinal hernia surgery.
Journal of surgical case reportsExpanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study on uncommon peritoneal malignancies.
World journal of clinical oncologyAscorbic Acid Analog 6-Deoxy-6-18F-Fluoro-l-Ascorbic Acid PET Imaging of 23 Various Cancer Types.
Journal of nuclear medicine : official publication, Society of Nuclear MedicineRethinking 'extreme' cytoreductive surgery in malignant peritoneal mesothelioma.
Acta chirurgica BelgicaThe Effect of Splenectomy on Postoperative Morbidity and Survival in Patients with Peritoneal Carcinomatosis.
Journal of clinical medicineMalignant peritoneal mesothelioma as a secondary cancer following radiotherapy for cervical cancer: a case report and literature review.
Gynecologic oncology reports[Occurrence of Malignant Peritoneal Mesothelioma 19 Years after Concurrent Chemoradiation Therapy for Uterine Cervical Cancer Stage ⅢB-A Case Report and Literature Review].
Gan to kagaku ryoho. Cancer & chemotherapyPeritoneal Mesothelioma Diagnosed on Frozen Section During Diagnostic Laparoscopy: A Case Report.
CureusMalignant peritoneal mesothelioma mimicking ovarian cancer: a diagnostic challenge.
BMJ case reportsAtypical abdominal pain: uncovering malignant peritoneal mesothelioma in suspected Crohn's disease: a case report.
Journal of gastrointestinal oncologyUse of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report.
The American journal of case reportsA Case of Primary Malignant Peritoneal Mesothelioma.
CureusDynamic evolution of NK cells and immune remodeling mediated by CRS + HIPEC: prognostic mechanisms and therapeutic implications for malignant peritoneal mesothelioma.
World journal of surgical oncologyCase Report: Malignant peritoneal mesothelioma with TFG-ROS1 fusion responds to crizotinib.
Frontiers in oncologyNon-Asbestos-Related Malignant Peritoneal Mesothelioma: A Diagnostic Challenge in a Case of Unexplained Ascites.
CureusComparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma.
Clinical Medicine Insights. OncologyAssessing the Annual Risk of Recurrence Following Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Diffuse Malignant Peritoneal Mesothelioma Patients.
Annals of surgical oncologyLong-term survival in peritoneal mesothelioma treated with 24 consecutive PIPACs.
Pleura and peritoneumASO Author Reflections: Malignant Peritoneal Mesothelioma Deserves Long-term Surveillance to Detect Locoregional as Systemic Late Recurrences.
Annals of surgical oncologyEfficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single-center retrospective study based on propensity score matching.
International journal of cancerSuccessful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports.
Case reports in oncologyA rare presentation of peritoneal mesothelioma: Esophageal encasement and Sister Mary Joseph nodule.
Radiology case reportsOptimizing the pathological diagnosis of diffuse malignant peritoneal mesothelioma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyYoung-onset epithelioid type malignant peritoneal mesothelioma with loss of BAP1 gene expression.
BMJ case reports[Malignant peritoneal mesothelioma detected by endoscopy after intractable stuttering:a case report].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterologyA giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature.
Journal of cancer research and therapeuticsPerisplenic mass as initial diagnosis of malignant peritoneal mesothelioma.
Zeitschrift fur GastroenterologieASO Author Reflections: Does More Lymphocyte Infiltration Indicate a Better Prognosis in Malignant Peritoneal Mesothelioma?
Annals of surgical oncologyHyperleukocytosis, leukemoid reaction caused by malignant peritoneal mesothelioma: a case report and review of literature.
Frontiers in oncologyClinical Significance of Tumor-Infiltrating Lymphocytes in Malignant Peritoneal Mesothelioma: A Single-Center Study of 143 Cases.
Annals of surgical oncologyEnhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report.
World journal of nuclear medicineSignificance of 18 F-fluorodeoxyglucose PET/computed tomography in the initial staging of malignant peritoneal mesothelioma.
Nuclear medicine communicationsNavigating Fertility Preservation in Epithelioid Peritoneal Mesothelioma: A Case Study.
The American journal of case reportsA challenging diagnosis of malignant peritoneal mesothelioma.
Internal and emergency medicineDevelopment and validation of a prognostic nomogram for patients with malignant peritoneal mesothelioma.
Frontiers in oncologyPembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long‑term survival: A case report and literature review.
Oncology lettersIncidental finding of metastatic mesothelioma in an inguinal hernia sac: a case report.
Journal of surgical case reportsSystemic Therapy and Surgical Management of Peritoneal Mesothelioma.
Surgical oncology clinics of North AmericaPrognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
BMC cancerAnalysis of TERT mRNA Levels and Clinicopathological Features in Patients with Peritoneal Mesothelioma.
Cancers68 Ga-FAPI PET/CT Depicted Non-FDG-Avid Malignant Peritoneal Mesothelioma.
Clinical nuclear medicineDiagnostic Differentiation Between Two Rare Entities-Metastatic Peritoneal Mesothelioma With Duodenal Involvement and Duodenal Synovial Sarcoma: A Case Report.
CureusCase report: Radiological features of a case of desmoplastic malignant mesothelioma of peritoneum.
Frontiers in oncologyImaging, pathological and molecular detection of malignant peritoneal mesothelioma (MPM): a case description.
Quantitative imaging in medicine and surgeryCytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Outcomes From a Tertiary Cancer Care Center in India.
CureusA Case Report of Peritoneal Mesothelioma as an Acute Abdomen Mimic: A Rare Presentation and Diagnostic Challenges.
CureusMultisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Diffuse Malignant Peritoneal Mesothelioma: A GRADE Approach for Evidence Evaluation and Recommendation.
Journal of surgical oncologyPrognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers.
Annals of surgical oncologyMalignant peritoneal mesothelioma interactome with 417 novel protein-protein interactions.
BJC reportsAscites as a Rare Manifestation of Malignant Peritoneal Mesothelioma: A Case Report.
CureusBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review).
Oncology lettersPotential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy.
Cancer biology & medicineAntigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma.
Scientific reportsSurgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma : A retrospective single center experience.
Wiener klinische WochenschriftMalignant STK11 adnexal tumor harboring a somatic mutation in a woman previously diagnosed with mesothelioma, a case report.
Gynecologic oncology reports68Ga-FAPI PET/CT findings of diffuse malignant peritoneal mesothelioma involving the gastrointestinal tract.
Japanese journal of clinical oncologyEffect of postoperative normothermic intraperitoneal chemotherapy on the prognosis of MPM patients receiving CRS+HIPEC: A single-center case-control study.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyPerfusion Strategies for Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma.
Journal of surgical oncologyDrug sensitivity tumor cell clusters in malignant peritoneal mesothelioma.
Journal of surgical oncologyCase report: ATM A1159T mutation in malignant peritoneal mesothelioma may be associated with tumor recurrence.
SAGE open medical case reportsMalignant peritoneal mesothelioma with liver metastasis: A case report and literature review.
Asian journal of surgeryDevelopment in the Study of Natural Killer Cells for Malignant Peritoneal Mesothelioma Treatment.
Cancer biotherapy & radiopharmaceuticalsMajor response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.
Frontiers in oncologyResearch progress of malignant peritoneal mesothelioma with paraneoplastic syndrome: A review.
Journal of surgical oncologyPrimary Peritoneal Mesothelioma Affecting the Greater Omentum That Mimicked an Omental Infarction: A Case Report.
Case reports in oncologyIncidental Diagnosis of Malignant Peritoneal Mesothelioma During Liver Transplantation Surgery: A Case Report.
The American journal of case reportsSpatial Landscape of Malignant Pleural and Peritoneal Mesothelioma Tumor Immune Microenvironments.
Cancer research communicationsASO Author Reflections: Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights from a Multi-center Study.
Annals of surgical oncologyIntra-Operative Diagnosis of Benign Multicystic Peritoneal Mesothelioma: A Case Report of Rare Entity and Lessons Learned.
CureusDual Malignancies Discovered: A Rare Case of Malignant Peritoneal Epithelioid Mesothelioma and Lung Adenocarcinoma.
CureusCurrent clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Innovative surgical sciencesCase report: Abdominal mesothelioma in Atelerix albiventris.
Frontiers in veterinary scienceAnalysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center Study.
Annals of surgical oncologyRapid Progression of Malignant Peritoneal Mesothelioma Mimicking a Postoperative Complication in a Young Woman: A Case Report.
The American journal of case reportsComprehensive genomic profiling of pediatric peritoneal mesothelioma: case report with a literature review.
Journal of surgical case reportsMalignant peritoneal mesothelioma presenting with bilateral hydronephrosis and renal insufficiency: a case report and literature review.
Frontiers in surgeryDiagnosis and treatment of malignant retroperitoneal mesothelioma: A case report.
MedicineHigh mobility group box 1 mediates inflammatory responses in malignant peritoneal mesothelioma.
International immunopharmacologyImplementation of a high-resolution, high-contrast magnetic resonance imaging protocol with extended delayed phases for peritoneal mesothelioma.
Quantitative imaging in medicine and surgeryPeritoneal Carcinomatosis: When Everything Is Not What It Seems.
CureusA Complete Response to Pembrolizumab in Malignant Peritoneal Mesothelioma: A Case Report.
CureusBuilding an Efficient Peritoneal Surface Malignancies Program Despite the Lower-Middle-Income Barriers: Ukraine Experience.
JCO global oncologyBiphasic Peritoneal Mesothelioma Is a Rare Tumor and a Diagnostic Challenge: A Case Report.
CureusIs extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?
Acta chirurgica BelgicaClinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: a case report and literature review.
Pathology oncology research : PORMalignant Peritoneal Mesothelioma Complicating Familial Mediterranean Fever on 18 F-FDG PET/CT.
Clinical nuclear medicineRisk factors and prognosis of malignant peritoneal mesothelioma with paraneoplastic syndrome.
World journal of surgical oncologyASO Author Reflections: Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma treated with CRS-HIPEC.
Annals of surgical oncologyOrganoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma.
Molecular cancerComplete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.
BMJ case reportsA 51-Year-Old Woman with Advanced Peritoneal Mesothelioma and Stage 3b Chronic Kidney Disease Treated with Cytoreductive Surgery and Bidirectional Intraperitoneal Cisplatin and Ifosfamide Chemotherapy: A Case Report.
The American journal of case reportsRandomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma.
International journal of surgery protocolsOral Anlotinib Maintenance Therapy for an Advanced Malignant Peritoneal Mesothelioma Diagnosed by Laparoscopy After Initial Misdiagnosis to Obtain Longer Progression-Free Survival: Case Report and Literature Review.
OncoTargets and therapyImpact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC.
Annals of surgical oncologyOutcomes Following Cytoreductive Surgery and Hyperthermic Intraoperative Thoraco-Abdominal Chemotherapy with Diaphragm Resection for Peritoneal Carcinomatosis: A Retrospective Cohort Study.
Annals of surgical oncologyMalignant Peritoneal Mesothelioma: An In-Depth and Up-to-Date Review of Pathogenesis, Diagnosis, Management and Future Directions.
CancersBrain Metastases With Malignant Peritoneal Mesothelioma: Never Reported Before.
CureusPrinciples of Surgical Management of Peritoneal Mesothelioma.
Journal of the National Comprehensive Cancer Network : JNCCNMalignant Peritoneal Mesothelioma: A Case Report.
CureusA case report of hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) for malignant peritoneal mesothelioma.
Asian journal of surgeryASO Author Reflections: International Standardization of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocols-Malignant Peritoneal Mesothelioma as a Model.
Annals of surgical oncologyZimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature.
World journal of clinical casesAdjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial.
Journal for immunotherapy of cancer[Pathological classification of malignant peritoneal mesothelioma and comparative analysis with peritoneal carcinomatosis].
Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseasesMetachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report.
Medicine2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma.
Annals of surgical oncologyRare Variants of Malignant Peritoneal Mesothelioma: a Literature Review.
Indian journal of surgical oncologyPeritoneal Mesothelioma: Systematic Review of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocol Outcomes.
Indian journal of surgical oncologyPerioperative Systemic Chemotherapy in Patients with Malignant Peritoneal Mesothelioma Undergoing Cytoreduction and HIPEC: Don't Put the Cart Before the Horse.
Annals of surgical oncologyEstablishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupDiffuse malignant peritoneal mesothelioma presenting as small bowel obstruction.
Radiology case reports[A case of malignant peritoneal mesothelioma].
Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseasesRecurrent malignant peritoneal mesothelioma treated by a second resection: A case report.
Clinical case reportsThe clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
Annals of diagnostic pathologyPrognostic significance of the immuno-peritoneal cancer index in peritoneal metastatic patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Langenbeck's archives of surgeryPrognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
BMC cancerASO Author Reflections: Contemporary Management Trends in Malignant Peritoneal Mesothelioma.
Annals of surgical oncologyNational Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
Annals of surgical oncologyMorphine poisoning in a patient with malignant peritoneal mesothelioma: A case report.
Experimental and therapeutic medicineSTRN-ALK rearranged malignant peritoneal mesothelioma-Presenting with bilateral extensive pelvic masses in a young woman: Mimicking low-grade serous ovarian carcinoma.
Indian journal of pathology & microbiology[A case of sarcomatoid intrahepatic cholangiocarcinoma that was difficult to diagnose].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterologyPeritoneal Mesothelioma in a High Volume Peritoneal Surface Malignancies Unit.
Journal of clinical medicineBidirectional Intraoperative Chemotherapy Using Cisplatin and Ifosfamide for Intraperitoneal Mesothelioma in Severe Renal Impairment: A Case Report.
The American journal of case reportsImmunotherapy in malignant peritoneal mesothelioma (Review).
Molecular and clinical oncologyClinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.
JAMA network openLong-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma.
Case reports in medicineCytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma.
Bratislavske lekarske listyThrombocytosis as a paraneoplastic syndrome in metastatic malignant peritoneal mesothelioma of biphasic morphology mimicking ovarian adenocarcinoma: A case report.
Clinical case reportsMalignant Peritoneal Mesothelioma With Butterfly-Shaped Muscle Metastasis: 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT.
Clinical nuclear medicineA case of malignant peritoneal mesothelioma with a Fitz-Hugh-Curtis syndrome-like imaging finding.
Clinical journal of gastroenterologyDiagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma.
CancersLong-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.
Annals of surgical oncologyCorrelation of serum-soluble mesothelin-related protein, HMGB1 and CA125 in diffuse malignant peritoneal mesothelioma and their combined measurement for prognosis.
Scandinavian journal of clinical and laboratory investigationDiffuse malignant peritoneal mesothelioma: A review.
Frontiers in surgeryUnusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports.
Case reports in oncologyPrimary Peritoneal Mesothelioma: Diagnostic Challenges of This Lethal Imposter.
Case reports in gastroenterologyContemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.
CancersImpact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centers.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologySynchronous Malignant Peritoneal Mesothelioma and Sigmoid Adenocarcinoma: a Challenging Clinical Entity.
Medical archives (Sarajevo, Bosnia and Herzegovina)Quantitative Assessment of Asbestos Fibers in Normal and Pathological Peritoneal Tissue-A Scoping Review.
Life (Basel, Switzerland)Malignant peritoneal mesothelioma-a diagnostic challenge.
Journal of surgical case reportsDelayed CRS-HIPEC Is Associated with Decreased Survival in Patients with Malignant Peritoneal Mesothelioma: A Markov Decision Analysis.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractSurvival analysis and development of a prognostic nomogram for patients with malignant mesothelioma in different anatomic sites.
Frontiers in oncologyMalignant Peritoneal Mesothelioma Features Shown by FDG-PET/CT.
Cancer diagnosis & prognosisPeritoneal mesothelioma causing small bowel obstruction in COVID-19 positive patient.
Journal of surgical case reportsLocalized malignant peritoneal mesothelioma presenting hepatohilar giant mass.
Oxford medical case reportsLoss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases.
World journal of surgical oncologyMalignant peritoneal mesothelioma with massive ascites as the first symptom: A case report.
World journal of clinical casesMalignant Peritoneal Mesothelioma.
Chonnam medical journalA single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma.
PloS oneDesmoid-type fibromatosis in the setting of malignant peritoneal mesothelioma: a case report of two rare diseases.
World journal of surgical oncologyClinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyMalignant peritoneal mesothelioma literature review: past, present, and future.
Digestive medicine researchMalignant Peritoneal Mesothelioma: A Challenging Case for Palliative Care.
CureusMalignant Peritoneal Mesothelioma Presenting with High Protein, High Serum-Ascites Albumin Gradient.
CureusConcurrent alcoholic cirrhosis and malignant peritoneal mesothelioma in a patient: A case report.
World journal of clinical casesAxillary lymph node metastasis as initial manifestation of malignant peritoneal mesothelioma; an unusual presentation.
Medical journal, Armed Forces IndiaNivolumab for pediatric malignant peritoneal mesothelioma.
Pediatric blood & cancerEfficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study.
Frontiers in oncologySubstance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.
International journal of molecular sciencesImproved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature.
Frontiers in pharmacologyAnalysis of malignant peritoneal mesothelioma treated by cryoablation combined with traditional Chinese medicine: A case report.
Asian journal of surgeryPrognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.
World journal of surgical oncologyTen-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Langenbeck's archives of surgeryIntraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO.
BMJ openLocalized Malignant Peritoneal Mesothelioma (LMPeM) in Women: A Clinicopathologic Study of 18 Cases.
The American journal of surgical pathologyMolecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
JCO precision oncologyClinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly.
BMC gastroenterologyPrimary malignant peritoneal mesothelioma mimicking tuberculous peritonitis: A case report.
World journal of clinical casesCytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre.
Anticancer research5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
Virchows Archiv : an international journal of pathologyDNA repair and damage pathways in mesothelioma development and therapy.
Cancer cell internationalNPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine.
World journal of surgical oncologyExpression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study.
The Journal of surgical researchKey factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia GroupDiffuse Peritoneal Malignant Mesothelioma Presenting with Abnormal Uterine Bleeding: Case Report.
Case reports in oncologyTreatment of Patients with Malignant Peritoneal Mesothelioma.
Journal of clinical medicineChallenging Diagnostic Process for a Malignant Peritoneal Mesothelioma Patient With Ascites and Pleural Effusion: A Case Report and Review of the Literature.
Frontiers in oncologyBiphasic Peritoneal Mesothelioma: A Lethal Clinical Entity.
CureusmiR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.
Cancer gene therapyThe role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.
Abdominal radiology (New York)CT imaging of malignant peritoneal mesothelioma: A case report.
Radiology case reportsDiffuse malignant peritoneal mesothelioma mimicking ovarian cancer.
Radiology case reportsHepatic bridge and round ligament of the liver during cytoreductive surgery: a retrospective cohort.
Langenbeck's archives of surgeryCommunicating imaging findings in peritoneal mesothelioma: the impact of 'PAUSE' on surgical decision-making.
Insights into imagingMalignant Peritoneal Mesothelioma With EWSR1-ATF1 Fusion: A Case Report.
JTO clinical and research reports[Malignant Peritoneal Mesothelioma Diagnosed as an Inguinal Mass : A Case Report].
Hinyokika kiyo. Acta urologica JaponicaThe Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma.
CureusTreatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma With Combination Chemoimmunotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997)Progression of Peritoneal Mesothelioma In Situ to Invasive Mesothelioma Arising in the Setting of Endometriosis With Germline BAP1 Mutation: A Case Report.
International journal of gynecological pathology : official journal of the International Society of Gynecological PathologistsNon-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study.
Annals of surgical oncologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Mesotelioma peritoneal maligno.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Mesotelioma peritoneal maligno
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Pretreatment volume-based 18F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients.
- Genomic sequencing of multicystic mesothelioma finds cohesin complex mutations associated with disease recurrence in patients referred for cytoreductive surgery and HIPEC.
- Ten-year of French multicentric experience in the management of peritoneal mesothelioma with 924 patients.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology· 2026· PMID 41785549mais citado
- Novel EWSR1::TEAD3 Fusion in an Adolescent With a Highly Aggressive Peritoneal Mesothelioma.
- Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:168811(Orphanet)
- MONDO:0005512(MONDO)
- GARD:20102(GARD (NIH))
- Busca completa no PubMed(PubMed)
- Q7168876(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
